Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
Prolactinoma
NEJM 349:2035-2041, Schlechte,J.A., 2003
Management of Pituitary Tumors
Ann Int Med 129:472-483, Shimon,I.&Melmed,S., 1998
Chiasmal Herniation as a Complication of Bromocriptine Therapy
J Neuro-Ophthalmol 16:252-257, Taxel,P.,et al, 1996
Postpartum Cerebral Angiopathy Possibly Due to Bromocriptine Therapy
Stroke 26:128-130, Janssens,E.,et al, 1995
Prolactin-Secreting Macroadenomas in Adolescents, Response to Bromocriptine Therapy
Am J Dis Child 147:1057-1061, Tyson,D.,et al, 1993
Diagnosis and Management of Hormone-Secreting Pituitary Adenomas
NEJM 324:822-831, Klibanski,A.&Zervas,N.T., 1991
Treatment of Prolactin-Secreting Pituitary Macroadenomas with the Long-Acting Non-Ergot Dopamine Agonist CV 205-502
Ann Int Med 112:668-673, Vance,M.L.,et al, 1990
Acromegaly
NEJM 322:966-977, Melmed,S., 1990
Hyperprolactinaemia, Common and Treatable
BMJ 297:701-702, Hartog,M.&Hull,M.G.R., 1988
Low Doses of Dopamine Agonists in the Long-Term Treatment of Macroprolactinomas
NEJM 313:656-659, Liuzzi,A.,et al, 1985
Effect of Dopamine Agonist Withdrawal After Long-Term Therapy in Prolactinomas
Lancet 2:187-192, Johnston,D.G.,et al, 1984
Reduction in Size of Prolactin-secreting Tumours in Men Treated with Pergolide
BMJ 285:465-467, Kendall-Taylor,P.,et al, 1982
The Prolactinoma Problem
NEJM 300:313-315, Reichlin,S., 1979
Drug Therapy, Bromocriptine
NEJM 301:873-878, Parkes,D., 1979
Prolactin-Secreting Tumors & Hypogonadism in 22 Men
NEJM 299:847-852, Carter,J.N.,et al, 1978